Cargando…

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

BACKGROUND: The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). An unmet need exists to identify patients with RCC who are most likel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motzer, Robert J, Choueiri, Toni K, McDermott, David F, Powles, Thomas, Vano, Yann-Alexandre, Gupta, Saurabh, Yao, Jin, Han, Celine, Ammar, Ron, Papillon-Cavanagh, Simon, Saggi, Shruti S, McHenry, M Brent, Ross-Macdonald, Petra, Wind-Rotolo, Megan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935174/ https://www.ncbi.nlm.nih.gov/pubmed/35304405 http://dx.doi.org/10.1136/jitc-2021-004316

Ejemplares similares

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Soluble PD-L1 as an early marker of progressive disease on nivolumab
por: Mahoney, Kathleen M, et al.
Publicado: (2022)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
por: Regan, Meredith M., et al.
Publicado: (2021)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
por: Larkin, James, et al.
Publicado: (2023)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
por: Motzer, Robert J, et al.
Publicado: (2021)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
por: Ross-Macdonald, Petra, et al.
Publicado: (2021)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
por: Shah, Manish A, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
por: Tykodi, Scott S, et al.
Publicado: (2022)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
por: Ready, Neal E, et al.
Publicado: (2023)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
por: Owonikoko, Taofeek K., et al.
Publicado: (2021)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Fukuda, Shohei, et al.
Publicado: (2021)

Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
por: Gorris, Mark A J, et al.
Publicado: (2022)

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma
por: Wang, Xuefeng, et al.
Publicado: (2022)

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

Predictive value of integrated (18)F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer
por: Umeda, Yukihiro, et al.
Publicado: (2020)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
por: Fizazi, Karim, et al.
Publicado: (2022)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
por: Sangro, Bruno, et al.
Publicado: (2023)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Schmidinger, M., et al.
Publicado: (2021)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
por: Ferris, Robert L, et al.
Publicado: (2021)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908
por: Dunkel, Ira J, et al.
Publicado: (2023)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p3qj47p261iliuft0fh3qi51mr